The implication of VRK1 in DDR [5,6,7,13,21,24] suggests that it may produce tumor resistance to DNA damaged-based therapies [34] which is consistent with its association to a poor clinical outcome in ER+ breast cancer. This evidence concerns the gene VRK1 and breast carcinoma.